Antibody Information
General Information of This Antibody
| Antibody ID | ANTI0GGDTY |
|||||
|---|---|---|---|---|---|---|
| Antibody Name | hz103E9B3H5L5 |
|||||
| Organization | CURON BIOPHARMACEUTICAL (SHANGHAI) CO., LIMITED |
|||||
| Synonyms |
hzl03E9B3H5L5
Click to Show/Hide
|
|||||
| Antibody Type | Monoclonal antibody (mAb) |
|||||
| Antibody Subtype | Humanized lgG1-kappa |
|||||
| Antigen Name | Neural cell adhesion molecule L1 (L1CAM) |
Antigen Info | ||||
| Click to Show/Hide the Sequence Information of This Antibody | ||||||
| Heavy Chain Sequence |
EVQLVQSGAEVKKPGASVKVSCKASGYTFTSYTMHWVRQAPGQGLEWMGDINPNYGGTSY
NEKFKDRVTMTTDTSTSTAYMELRSLRSDDTAVYYCAREGATGTWYFDVWGQGTTVTVSS ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSS GLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGG PSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVIHNAKTKPREEQY NSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRE EMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSR WQQGNVFSCSVMHEALIHNHYTQKSLSLSPGK Click to Show/Hide
|
|||||
| Heavy Chain Varible Domain |
EVQLVQSGAEVKKPGASVKVSCKASGYTFTSYTMHWVRQAPGQGLEWMGDINPNYGGTSY
NEKFKDRVTMTTDTSTSTAYMELRSLRSDDTAVYYCAREGATGTWYFDVWGQGTTVTVSS Click to Show/Hide
|
|||||
| Heavy Chain CDR 1 |
GYTFTSYT
Click to Show/Hide
|
|||||
| Heavy Chain CDR 2 |
INPNYGG
Click to Show/Hide
|
|||||
| Heavy Chain CDR 3 |
AREGATGTWYFDV
Click to Show/Hide
|
|||||
| Light Chain Sequence |
DIQMTQSPSSLSASVGDRVTITCSASSSVSFMFWYQQKPGKAPKPLIYLTSNLASGVPSR
FSGSGSGTDFTLTISSLQPEDFATYYCQQWRSNPPTFGGGTKVEIKRTVAAPSVFIFPPS DEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTL SKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC Click to Show/Hide
|
|||||
| Light Chain Varible Domain |
DIQMTQSPSSLSASVGDRVTITCSASSSVSFMFWYQQKPGKAPKPLIYLTSNLASGVPSR
FSGSGSGTDFTLTISSLQPEDFATYYCQQWRSNPPTFGGGTKVEIK Click to Show/Hide
|
|||||
| Light Chain CDR 1 |
SSVSF
Click to Show/Hide
|
|||||
| Light Chain CDR 2 |
LTS
Click to Show/Hide
|
|||||
| Light Chain CDR 3 |
QQWRSNPPT
Click to Show/Hide
|
|||||
Each Antibody-drug Conjugate Related to This Antibody
Full Information of The Activity Data of The ADC(s) Related to This Antibody
hz103E9B3H5L5-MMAE [Investigative]
Revealed Based on the Cell Line Data
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal inhibitory Concentration (lC50) |
0.32 nM
|
High L1CAM expression (L1CAM +++) | ||
| Method Description |
HeLa cells are cultured in DMEM complete medium (Corning, 10-013-CVR) containing 10% FBS (Gibco, 10099-141) and 100 U/mL penicillin-streptomycin mixture (Thermofisher, 15140122). When the cell coverage in the culture container reaches 80-90%, TrypLE (Thermofisher, 12604-013) is used to digest the HeLa cells from the culture container, and they are seeded in a 96-well cell culture plate (Greiner, 655098) at a density of 3.3X103 cells/mL, with 500 cells per well (145uL complete medium),and the 96-well plate is incubated at 37°C overnight. The next day, (ADC) is diluted in complete medium in a 4-fold serial dilution, with 9 concentration gradient points. Then, 5uL of dilution of the ADC molecule is added to each well in the 96-well cell culture plate, gently mixed, and the 96-well plate is incubated at 37°C for 6 days. Finally, 75 uL of CTG is added to each well, gently mixed, and the 96-well plate is incubated at room temperature for 10 minutes. Then the luminescence signal is detected using a multimode microplate reader (PerkinElmer Envision 2105). A dose-inhibition curve is generated, and the half-maximal inhibitory concentration (IC50) is calculated using non-linear regression with GraphPad software.
Click to Show/Hide
|
||||
| In Vitro Model | Endocervical adenocarcinoma | HeLa cells | CVCL_0030 | ||
| Experiment 2 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal inhibitory Concentration (lC50) |
91 nM
|
Low L1CAM expression (L1CAM+) | ||
| Method Description |
HeLa L1CAM-KO cells are cultured in DMEM complete medium (Corning, 10-013-CVR) containing 10% FBS (Gibco, 10099-141) and 100 U/mL penicillin-streptomycin mixture (Thermofisher, 15140122). When the cell coverage in the culture container reaches 80-90%, TrypLE (Thermofisher, 12604-013) is used to digest the HeLa L1CAM-KO cells from the culture container, and they are seeded in a 96-well cell culture plate (Greiner, 655098) at a density of 3.3X103 cells/mL, with 500 cells per well (145uL complete medium),and the 96-well plate is incubated at 37°C overnight. The next day, (ADC) is diluted in complete medium in a 4-fold serial dilution, with 9 concentration gradient points. Then, 5uL of dilution of the ADC molecule is added to each well in the 96-well cell culture plate, gently mixed, and the 96-well plate is incubated at 37°C for 6 days. Finally, 75 uL of CTG is added to each well, gently mixed, and the 96-well plate is incubated at room temperature for 10 minutes. Then the luminescence signal is detected using a multimode microplate reader (PerkinElmer Envision 2105). A dose-inhibition curve is generated, and the half-maximal inhibitory concentration (IC50) is calculated using non-linear regression with GraphPad software.
Click to Show/Hide
|
||||
| In Vitro Model | Human papillomavirus-related endocervical adenocarcinoma | HeLa cells (L1CAM KO) | CVCL_0030 | ||
